UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial

European heart journal, 2015-05, Vol.36 (19), p.1186-1194

2015

Volltextzugriff (PDF)

Safety and Efficacy of a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease, SAR236553/REGN727, in Patients With Primary Hypercholesterolemia Receiving Ongoing Stable Atorvastatin Therapy

Journal of the American College of Cardiology, 2012-06, Vol.59 (25), p.2344-2353

2012

Volltextzugriff (PDF)

National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 1—Full Report

Journal of clinical lipidology, 2015-03, Vol.9 (2), p.129-169

2015

Volltextzugriff (PDF)

Atorvastatin with or without an Antibody to PCSK9 in Primary Hypercholesterolemia

The New England journal of medicine, 2012-11, Vol.367 (20), p.1891-1900

2012

Volltextzugriff (PDF)

Effect of Alirocumab, a Monoclonal Proprotein Convertase Subtilisin/Kexin 9 Antibody, on Lipoprotein(a) Concentrations (a Pooled Analysis of 150 mg Every Two Weeks Dosing from Phase 2 Trials)

The American journal of cardiology, 2014-09, Vol.114 (5), p.711-715

2014

Volltextzugriff (PDF)

National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1 – executive summary

Journal of clinical lipidology, 2014-09, Vol.8 (5), p.473-488

2014

Volltextzugriff (PDF)

Effect of ETC-1002 on Serum Low-Density Lipoprotein Cholesterol in Hypercholesterolemic Patients Receiving Statin Therapy

The American journal of cardiology, 2016-06, Vol.117 (12), p.1928-1933

2016

Volltextzugriff (PDF)

Safety Considerations with Fibrate Therapy

The American journal of cardiology, 2007-03, Vol.99 (6), p.S3-S18

2007

Volltextzugriff (PDF)

Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial)

The American journal of cardiology, 2003-07, Vol.92 (2), p.152-160

2003

Volltextzugriff (PDF)

Understanding PCSK9 and anti-PCSK9 therapies

Journal of clinical lipidology, 2015-03, Vol.9 (2), p.170-186

McKenney, James M., PharmD, FAHA, FNLA

2015

Volltextzugriff (PDF)

Final Conclusions and Recommendations of the National Lipid Association Statin Safety Assessment Task Force

The American journal of cardiology, 2006-04, Vol.97 (8), p.S89-S94

2006

Volltextzugriff (PDF)

Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance

Journal of clinical lipidology, 2016-05, Vol.10 (3), p.556-567

2016

Volltextzugriff (PDF)

Lipid lowering with bempedoic acid added to a proprotein convertase subtilisin/kexin type 9 inhibitor therapy: A randomized, controlled trial

Journal of clinical lipidology, 2021-07, Vol.15 (4), p.593-601

2021

Volltextzugriff (PDF)

Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients

The American heart journal, 2009-02, Vol.157 (2), p.352-360.e2

2009

Volltextzugriff (PDF)

Role of Prescription Omega-3 Fatty Acids in the Treatment of Hypertriglyceridemia

Pharmacotherapy, 2007-05, Vol.27 (5), p.715-728

2007

Volltextzugriff (PDF)

Efficacy and Safety of Alirocumab Versus Ezetimibe Over 2 Years (from ODYSSEY COMBO II)

The American journal of cardiology, 2017-09, Vol.120 (6), p.931-939

2017

Volltextzugriff (PDF)

Protective effects of NAMPT or MAPK inhibitors and NaR on Wallerian degeneration of mammalian axons

Neurobiology of disease, 2022-09, Vol.171, p.105808-105808, Article 105808

2022

Volltextzugriff (PDF)

Something important is missing in the ACC/AHA cholesterol treatment guidelines

Journal of the American Pharmacists Association, 2015-05, Vol.55 (3), p.324-329

McKenney, James M., PharmD

2015

Volltextzugriff (PDF)

ODYSSEY MONO: effect of alirocumab 75 mg subcutaneously every 2 weeks as monotherapy versus ezetimibe over 24 weeks

Future cardiology, 2015-01, Vol.11 (1), p.27-37

2015

Volltextzugriff (PDF)

Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin

Journal of the American College of Cardiology, 2006-11, Vol.48 (9), p.1782

2006

Volltextzugriff (PDF)

Efficacy and Safety of Torcetrapib, a Novel Cholesteryl Ester Transfer Protein Inhibitor, in Individuals With Below-Average High-Density Lipoprotein Cholesterol Levels

Journal of the American College of Cardiology, 2006-11, Vol.48 (9), p.1774-1781

2006

Volltextzugriff (PDF)

Prescription omega-3 fatty acids for the treatment of hypertriglyceridemia

American journal of health-system pharmacy, 2007-03, Vol.64 (6), p.595-605

2007

Volltextzugriff (PDF)

Effect of PCSK9 Inhibition by Alirocumab on Lipoprotein Particle Concentrations Determined by Nuclear Magnetic Resonance Spectroscopy

Journal of the American Heart Association, 2015-11, Vol.4 (11)

2015

Volltextzugriff (PDF)

1 – 25 von 469

Suche als RSS-Feed

Aktive Filter

PublikationsformTexte

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(379)
Mit Volltextzugriff
(356)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(468)

Erscheinungsjahr

n.n

Thema

Science & Technology
(241)
Life Sciences & Biomedicine
(214)
Humans
(203)
Male
(127)
Female
(100)
Middle Aged
(93)
Biological And Medical Sciences
(85)
Medical Sciences
(78)
Pharmacology & Pharmacy
(67)
Aged
(65)
Adult
(63)
Cardiovascular System & Cardiology
(49)
Cardiac & Cardiovascular Systems
(48)
Cholesterol, Ldl - Blood
(44)
Double-Blind Method
(42)
Cardiovascular
(41)
Pharmacology. Drug Treatments
(40)
Hypercholesterolemia - Drug Therapy
(39)
Treatment Outcome
(38)
Hydroxymethylglutaryl-Coa Reductase Inhibitors - Therapeutic Use
(32)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial

Safety and Efficacy of a Monoclonal Antibody to Proprotein Convertase Subtilisin/Kexin Type 9 Serine Protease, SAR236553/REGN727, in Patients With Primary Hypercholesterolemia Receiving Ongoing Stable Atorvastatin Therapy

National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 1—Full Report

Atorvastatin with or without an Antibody to PCSK9 in Primary Hypercholesterolemia

Effect of Alirocumab, a Monoclonal Proprotein Convertase Subtilisin/Kexin 9 Antibody, on Lipoprotein(a) Concentrations (a Pooled Analysis of 150 mg Every Two Weeks Dosing from Phase 2 Trials)

National Lipid Association recommendations for patient-centered management of dyslipidemia: Part 1 – executive summary

Effect of ETC-1002 on Serum Low-Density Lipoprotein Cholesterol in Hypercholesterolemic Patients Receiving Statin Therapy

National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2

Safety Considerations with Fibrate Therapy

Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial)

Understanding PCSK9 and anti-PCSK9 therapies

Final Conclusions and Recommendations of the National Lipid Association Statin Safety Assessment Task Force

Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance

Lipid lowering with bempedoic acid added to a proprotein convertase subtilisin/kexin type 9 inhibitor therapy: A randomized, controlled trial

Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients

Role of Prescription Omega-3 Fatty Acids in the Treatment of Hypertriglyceridemia

Efficacy and Safety of Alirocumab Versus Ezetimibe Over 2 Years (from ODYSSEY COMBO II)

Protective effects of NAMPT or MAPK inhibitors and NaR on Wallerian degeneration of mammalian axons

Something important is missing in the ACC/AHA cholesterol treatment guidelines

ODYSSEY MONO: effect of alirocumab 75 mg subcutaneously every 2 weeks as monotherapy versus ezetimibe over 24 weeks

Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin

Efficacy and Safety of Torcetrapib, a Novel Cholesteryl Ester Transfer Protein Inhibitor, in Individuals With Below-Average High-Density Lipoprotein Cholesterol Levels

Clinical utility of inflammatory markers and advanced lipoprotein testing: Advice from an expert panel of lipid specialists

Prescription omega-3 fatty acids for the treatment of hypertriglyceridemia

Effect of PCSK9 Inhibition by Alirocumab on Lipoprotein Particle Concentrations Determined by Nuclear Magnetic Resonance Spectroscopy

Aktive Filter

Suchergebnisse filtern